Four years of hard work were rewarded yesterday with a wonderful PhD and PhD defence by @FlorVerghote ! The results of this research contribute to a better understanding of the role of radiotherapy in bladder cancer. Proud to have been your supervisor with @CharlesPraet !

Honoured to had the opportunity to discuss the place of Adjuvant Radiotherapy for bladder Cancer and presenting the results of the Belgian trial supporting this approach! Motivated to proceed with our ongoing EFFORT trial! @FlorVerghote @camilleberquin @daandm @uzgent @ugent

High-risk biochemical recurrence with positive PSMA PET: Radiotherapy still matters. Presentation by @fontev1 @uzgent. #EAU25 written coverage by @RKSayyid @USC > https://t.co/8z3690IrF5 @Uroweb

I usually don’t post political views but now….

Updated results by @FlorVerghote of the Belgian trial on Adjuvant Radiotherapy for MIBC! Awaiting the results of the trials by @PaulSargos and @VedangMurthy @ugent @uzgent @camilleberquin @CharlesPraet @Xristodouleas @BrianBaumannMD https://t.co/7Vowx2JjTj

Does SBRT for oligorecurrent #prostatecancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO. Presented by @ChadTangMD at #GU25.

Recap of a first excellent day of the Belgian Urology Conference in Spa! Kudos to @AFSpinoit for the great organization! And endlessly proud of our team 💪🏽 @uzgent @ugent_fge @DrHerve_urology @CharlesPraet @mwaterloos1 @fontev1 #BAU24

@drenriquegrande @urotoday @DrOmarMian @fredhutch @RKSayyid For sure underutilized. ⚡ Safe and efficient with many prospective data available.. And many to come! @VedangMurthy @jnt_khalifa @fontev1 @BrianBaumannMD @Xristodouleas @GETUG_Unicancer

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 https://t.co/dyTV0eN9zy The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in

We learned a lot about muscle-invasive bladder cancer this past week. Together, these studies suggest that a strategy worth exploring is to further de-intensify surgical lymph node management to reduce surgery-related mortality, while using adjuvant radiation to treat nodes in

Interested in reading the protocol? https://t.co/tyDavqw1zI Interested in the early results? Coming soon at a conference near you! #BladderCancerAwarenessMonth 🧡 @BladderCancerUK @BladderCancerUS @UroDocAsh @shilpaonc @neerajaiims @fontev1

#ESTRO24 @FlorVerghote adding to the emerging role of adjuvant RT for bladder cancer Intriguing that only 3/14 pts with positive surgical margins had pelvic failures #radonc

@joniau @MaartenAlbersen @DrShariat @tompowles1 @ThRoumeguere @KarelDecaestec1 @fontev1 @LoicBaekelandt @GertMeerleer @BertrandTOMBAL @LorenzoTOSCO @KatoRans @Eduardrssl @ESRUrology @BVUrologie @sb_uro

3-year toxicity after moderate hypofractionated radiotherapy: a Belgian phase 3 trial adding to the evidence that moderate hypofractionated radiotherapy is feasible in unselected prostate cancer patients. Teamwork @uzgent @Universiteit Gent https://t.co/w9uF5iA69d

Is there a role for stereotactic radiotherapy in selected patients with metastatic castrate-resistant #ProstateCancer? Check out this presentation by @fontev1 @ugent. #GU24 written coverage by @RKSayyid @UofT on UroToday > https://t.co/sTTPmqTgij @ASCO

Looking forward to present at #GU24: Treatment intensification: what to do for patients with early castration-resistant PCa who received doublet or triplet therapy. Is there a place for Stereotactic Radiotherapy?

Not convinced that IO is the first and only option here. Is it really an ‘adj RT or IO’ story or can it be a (sequential) ‘adj RT+IO’ story? @PaulSargos @VedangMurthy @FlorVerghote @BrianBaumannMD @Xristodouleas

3) prospective trials show that adj RT is well tolerated and reduces risk of locoregional relapse 4) locoregional relapse is associated with very poor survival and can impact QOL dramatically

🤔@#BLADDR23: case by @evacomperat and Javier Puente: ypT3N0M0 R1: what next? Majority votes for adjuvant IO, 1/4 for adjuvant RT. Concerns: 1) does R1 size matters: is’nt positive, positive? 2) IO is great (for the happy few?) but R1 pt were not included in adj IO trials

At #BLADDR23: great talk by @PaulSargos on role of adjuvant Radiotherapy in R1 MIBC: what are we doing differentially nowadays? 1) we have better criteria for patiënt selection 2) we have international guidelines on target delineation 3) we apply modern RT techniques